Using REMS to block generic sample access may violate antitrust laws, says US FTC
This article was originally published in SRA
Executive Summary
The Generic Pharmaceutical Association (GPhA), which lately has been on the opposing side of the US Federal Trade Commission, gave the agency a big pat on the back on 13 March after the government watchdog declared that refusal by a brand-name firm to sell drug samples to potential generic competitors may violate antitrust laws1,2.